Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 27;9(9):2780.
doi: 10.3390/jcm9092780.

Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors

Affiliations

Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors

Antonio Vena et al. J Clin Med. .

Abstract

We aimed to assess the prevalence of and factors associated with anti- severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) positivity in a large population of adult volunteers from five administrative departments of the Liguria and Lombardia regions. A total of 3609 individuals were included in this analysis. Participants were tested for anti-SARS-CoV-2 antibodies [Immunoglobulin G (IgG) and M (IgM) class antibodies] at three private laboratories (Istituto Diganostico Varelli, Medical Center, and Casa della Salute di Genova). Demographic data, occupational or private exposure to SARS-CoV-2-infected patients, and prior medical history consistent with SARS-CoV-2 infection were collected according to a preplanned analysis. The overall seroprevalence of anti-SARS-CoV-2 antibodies (IgG and/or IgM) was 11.0% [398/3609; confidence interval (CI) 10.0%-12.1%]. Seroprevalence was higher in female inmates than in male inmates (12.5% vs. 9.2%, respectively, p = 0.002), with the highest rate observed among adults aged >55 years (13.2%). A generalized estimating equations model showed that the main risk factors associated with SARS-CoV-2 seroprevalence were the following: an occupational exposure to the virus [Odd ratio (OR) = 2.36; 95% CI 1.59-3.50, p = 0.001], being a long-term care facility resident (OR = 4.53; 95% CI 3.19-6.45, p = 0.001), and reporting previous symptoms of influenza-like illness (OR = 4.86; 95% CI 3.75-6.30, p = 0.001) or loss of sense of smell or taste (OR = 41.00; 95% CI 18.94-88.71, p = 0.001). In conclusion, we found a high prevalence (11.0%) of SARS-CoV-2 infection that is significantly associated with residing in long-term care facilities or occupational exposure to the virus. These findings warrant further investigation into SARS-CoV-2 antibody prevalence among the Italian population.

Keywords: COVID-19; SARS-CoV-2; antibodies; serological test.

PubMed Disclaimer

Conflict of interest statement

Outside the submitted work, M.B. (Matteo Bassetti) has participated in advisory boards and/or received speaker honoraria from Achaogen, Angelini, Astellas, Bayer, Basilea, BioMeérieux, Cidara, Gilead, Menarini, MSD, Nabriva, Paratek, Pfizer, Roche, Melinta, Shionogi, Tetraphase, VenatoRx, and Vifor and has received study grants from Angelini, Basilea, Astellas, Shionogi, Cidara, Melinta, Gilead, Pfizer, and MSD. Outside the submitted work, D.R.G. reports honoraria from Stepstone Pharma GmbH and unconditional grants from MSD Italia and Correvio Italia. The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Serologically-confirmed cases of SARS-CoV-2 in the general Italian population from 1 March to 30 April 2020. Red and blue lines represent the boarders of the Lombardia and Liguria regions, respectively. Percentages show the number of positive samples per number tested in each administrative department.

Similar articles

Cited by

References

    1. Onder G., Rezza G., Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020;323:1775–1776. doi: 10.1001/jama.2020.4683. - DOI - PubMed
    1. [(accessed on 30 April 2020)]; Available online: http://www.salute.gov.it/portale/nuovocoronavirus/
    1. Bassetti M., Vena A., Giacobbe D.R. The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm. Eur. J. Clin. Investig. 2020;50:e13209. doi: 10.1111/eci.13209. - DOI - PMC - PubMed
    1. Kim G.U., Kim M.J., Ra S.H., Lee J., Bae S., Jung J., Kim S.-H. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin. Microbiol. Infect. 2020;26:948.e1–948.e3. doi: 10.1016/j.cmi.2020.04.040. - DOI - PMC - PubMed
    1. Mizumoto K., Kagaya K., Zarebski A., Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance. 2020;25:2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180. - DOI - PMC - PubMed

LinkOut - more resources